HeLa cells were used by Jonas Salk to test the first polio vaccine in the 1950s. They were observed to be easily infected by poliomyelitis, causing infected cells to die. This made HeLa cells highly desirable for polio vaccine testing since results could be easily obtained. A large volume of HeLa cells were needed for the testing of Salk's polio vaccine, prompting the National Foundation for Infantile Paralysis (NFIP) to find a facility capable of mass-producing HeLa cells. In the spring of 1953, a cell culture factory was established at Tuskegee University to supply Salk and other labs with HeLa cells.
Remune P < 0.05 & HIV-1 lymphocyte proliferation P < 0.001 both favoring the Remune Group. The International AIDS Vaccine Research (IAVA) issued a report on “Whole Killed AIDS Vaccines” in 1999 reviewing a diverse aspect of the killed virus approach. Remune Remune is the first therapeutic HIV vaccine based on the killed whole virus approach. Remune was initially invented by Jonas Salk in 1987 and is now being developed by Immune Response BioPharma, Inc. (IRBP) Remune is a therapeutic HIV/AIDS vaccine that has completed over 25 clinical studies to date and shows a robust mechanism of action restoring white blood